Abstract: The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: Disclosed herein is an automated urinary output measuring system. The automated urinary output measuring system includes an automated urinary output measuring device configured to be suspended from a rim of a sanitary hardware device and receive a volume of voided urine. The automated urinary output measuring device can include a receiving trough having an opening, a door configured to cover the opening in a fluid tight seal, the door coupled to the receiving trough by a hinge, and a lip extending from the receiving trough configured to detachably couple the automated urinary output measuring device to the sanitary hardware device. The system can further include an ultrasonic measuring system having a console coupled to one or more ultrasonic sensors, and a flushing mechanism coupled to the sanitary hardware device.

Abstract: Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: A computer-implemented method is disclosed for candidate antibody exploration. The method includes receiving sequence reads from a sequencing system, wherein each sequence read comprises a target gene for expressing a candidate antibody, wherein each sequence read is associated with a binding affinity to a target antigen. The method includes generating a sequence representation for each sequence read, representing the amino acid sequences of the sequence read. The method includes training a binding affinity prediction model with the sequence representations and the binding affinities. The method includes generating a synthetic candidate sequence read that is different from the sequence reads. The method includes generating a sequence representation for the synthetic candidate sequence read.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Abstract: Machine-learning (ML) techniques and models are described for predicting the number and severity of network attacks within a specified timeframe, such as the next fifteen minutes. In some embodiments, the techniques including training a ML model based on features extracted from a training dataset and applying the trained ML model to estimate (a) the probability of an attack happening on an account within a specified timeframe; (b) how many attacks are predicted to occur in the specified timeframe (if any); and/or (c) the severity of the attacks predicted to occur. A system may deploy preventative measures based on the ML model output to counter or mitigate the effects of predicted and coordinated network attacks.

Abstract: Machine-learning techniques and models are described for alerting users to attacks on accounts in real-time or near real-time. In some embodiments, an attack detection model uses Natural Language Processing (NLP) and multi-level classification techniques to monitor login attempts and detect attacks. The model may use NLP to convert text associated with account activity to numerical vectors, where the vectors include scores and/or other numerical values computed based on the meaning of the converted text. The model may further include a set of classifiers trained to learn patterns in the numerical vectors that are predictive of a network attack. The model may assign labels to events based on the predicted likelihood that the event is an attack. The system may deploy real-time preventative or corrective measures based on the ML model output to counter or mitigate the effects of an attack.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: A poroelastic biomaterial including a polyaryletherketone (PAEK) matrix polymer and a plurality of tortuous channels extending from one surface to another surface of the biomaterial is disclosed. Advantageously, the poroelastic biomaterial can have a porosity from about 5% to about 40% and high mechanical properties. The poroelastic biomaterials can be fabricated into orthopedic implant devices and can be used as a tissue scaffolds.

Abstract: Disclosed embodiments provide a computer-implemented technique for creating a log chain from multiple software component logs. The log chain can include log information from multiple software components that interact with each other. In embodiments, a locality-sensitive hashing technique is used to create a signature of a log chain. Machine-learning systems are trained with log chains generated from test execution, and/or log chains from incidents with deployed software. In embodiments, logs are pre-processed by tokenizing and trimming. Logs from various components that interact with each other may be combined into a temporally sequential log chain. The signature of the log chain may be used to identify additional information about the error from a machine-learning process that was trained on previously generated log chains. In this way, the time required to identify a problem can be significantly reduced, resulting in increased reliability and availability of complex computer systems.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.